Drug-induced diseases: epidemiology and urgency of the problem


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The high incidence of drug-induced diseases (DIDs) and the diversity of their clinical manifestations make this problem relevant for doctors of all specialties. Often, practicing doctors do not recognize adverse drug effects insufficiently, and sometimes they do not recognize them at all. This is due to the fact that very often symptoms of the disease can be easily confused with the side effects of drugs. The article analyzes the data of numerous studies on the problem of DIDs. Information on the prevalence, clinical manifestations, hospitalization statistics, mortality, and material costs associated with the development of DIDs is presented. Early detection and correction of side effects can help reduce morbidity and mortality, so this problem is extremely important.

Толық мәтін

Рұқсат жабық

Авторлар туралы

D. Sychev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: ostroumova.olga@mail.ru
Dr. Sci. (Med.), Professor of the Department of Therapy and Polymorbid Pathology 2/1, Barrikadnaya str., Moscow 125993, Russian Federation

A. Kochetkov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

A. Pereverzev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

T. Ostroumova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, Russia

M. Klepikova

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

I. Alyautdinova

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

E. Ebzeeva

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

Әдебиет тізімі

  1. Kantor E., Rehm C., Haas J.S., et al. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-31. doi: 10.1001/jama.2015.13766.
  2. Tisdale J.E., Miller D.A. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018. 1399 р.
  3. Hales C.M., Servais J., Martin C.B., Kohen D. Prescription Drug Use Among Adults Aged 40-79 in the United States and Canada. NCHS Data Brief. 2019;(347):1-8.
  4. Сычев Д.А. (ред.). Полипрагмазия в клинической практике: проблема и решения. Учебное пособие. 2-е изд., испр. и доп. СПб., 2018. 272 с, ил.
  5. Kaplowitz N., DeLeve L.D. Drug-Induced Liver Disease. Third edition. Elsevier Sci. 2013. 1693 р.
  6. Factor S.A., Lang A.E., Weiner W.J. (ed.). Drug Induced Movement Disorders. Second edition. Wiley-Blackwell, 2008. 480 p.
  7. Drug-Induced Dementia: A Perfect Crime. Jackson G.E. Authorhouse. USA; 2009. 464 р.
  8. Begaud B. Dictionary of pharmacoepidemiology. Chichester, England: John Wiley and Sons; 2000. 182 p.
  9. Hallis J. Drug related hospital admissions in subspecialties of internal medicine. Dan. Med. Bull. 1996;43(2):141-55.
  10. Naranjo C.A., Busto U., Sellers E.M., et al. A metod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. doi: 10.1038/clpt.1981.154.
  11. Institute for the Safety of Medicine. Quarter Watch. 2015 annular report (June 29, 2016). https:// www.ismp.org/quaterwatch/pdfs/2015Q4.pdf (accessed 2018 Jan 29).
  12. Bouvy J.C., De Bruin M.L., Koopmanschap M.A. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf. 2015;38(5):437-53. Doi: 10.1007/ s40264-015-0281-0. doi: 10.1371/journal. pone.0073166.
  13. Hakkarainen K.M., Andersson Sundel K., Petzold M., Hagg S. Prevalence and perceived preventability of self-reported adverse drug events: a population-based survey of 7099 adults. PLoS One. 2013;8(9):e73166.
  14. Hakkarainen K.M., Gyllensten H., Jonsson A.K., et al. Prevalence, nature and potential preventability of adverse drug events: a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170-83. doi: 10.1111/bcp.12314.
  15. Letrilliart L., Hanslik T., Biour M., et al. Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study. Drug Saf. 2001;24(10):781-92. doi: 10.2165/00002018-200124100-00006.
  16. Khalil H., Huang C. Adverse drug reactions in primary care: a scoping review BMC Health Serv Res. 2020;20(1):5. Doi: https://doi.org/10.1186/s12913-019-4651-7
  17. Jacobs T.Q., Ross A. Adverse effects profile of multidrug-resistant tuberculosis treatment in a south African outpatient clinic. S Afr Fam Pract. 2012;54(6):531-39. doi: 10.1080/20786204.2012.10874288.
  18. Wucherer D., Thyrian J.R., Eichler T., et al. Drug related problems in community-dwelling primary care patients screened positive for dementia. Int. Psychogeriatr. 2017;29(11):1857-68. doi: 10.1017/S1041610217001442.
  19. Gandhi T.K., Weingart S.N., Borus J., et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556-64. Doi: 10.1056/ NEJMsa020703.
  20. Gurwitz J.H., Field T.S., Judge J., et al. The incidence of adverse drug events in two large academic longterm care facilities. Am J Med. 2005;118(3):251-58. doi: 10.1016/j.amjmed.2004.09.018.
  21. Aagaard L., Strandell J., Melskens L., et al. Global patterns of adverse drug reactions over a decade. Drug Saf. 2012;35(12):1171-82. doi: 10.2165/11631940-000000000-00000.
  22. Kaushal R., Goldmann D.A., Keohane C.A., et al. Adverse drug events in pediatric outpatients. Ambul Pediatr. 2007;7(5):383-89. doi: 10.1016/j.ambp.2007.05.005.
  23. Kowski A.B., Weissinger F., Gaus V, et al. Specific adverse effects of antiepileptic drugs-a true-to-life monotherapy study Epilepsy Behav. 2016;54:150-7. doi: 10.1016/j.yebeh.2015.11.009.
  24. Milligan F. Diabetes medication incidents in the care home setting. Nurs Stand. 2012;26(29):38-43. doi: 10.7748/ns2012.03.26.29.38.c8999.
  25. Montserrat-Capella D., Suarez M., Ortiz L., et al. AMBEAS Group. Frequency of ambulatory care adverse events in Latin American countries: the AMBEAS/PAHO cohort study. Int J Qual Health Care. 2015;27(1):52-9. doi: 10.1093/intqhc/mzu100.
  26. Schildmeijer K.G., Unbeck M., Ekstedt M., et al. Adverse events in patients in home healthcare: a retrospective record review using trigger tool methodology. BMJ. Open. 2018;8(1):e019267. doi: 10.1136/bmjopen-2017-019267.
  27. Tsang C., Majeed A., Banarsee R., Gnani S., Aylin P Recording of adverse events in English general practice: analysis of data from electronic patient records. Inform. Primary Care. 2010;18(2):117-24. doi: 10.14236/jhi.v18i2.761.
  28. Tomlin A., Reith D., Dovey S., Tilyard M. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records. Drug Saf. 2012;35(9):733-43. doi: 10.2165/11631970-000000000-00000.
  29. Woods D.M., Thomas E.J., Holl J.L., Weiss K.B., Brennan T.A. Ambulatory care adverse events and preventable adverse events leading to a hospital admission. Quality Saf Health Care. 2007;16(2):127-31. doi: 10.1136/qshc.2006.021147.
  30. Tache' S.V, Sönnichsen A., Ashcroft D.M. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7-8):977-89. doi: 10.1345/aph.1P627.
  31. Kongkaew C., Noyce F.I.R., Ashcroft D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-25. doi: 10.1345/aph.1L037.
  32. Al Hamid A., Ghaleb M., Aljadhey H., Aslanpour Z. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol. 2013;78(2):202-17. doi: 10.1111/bcp.12293.
  33. Angamo M.T., Chalmers L., Curtain C.M., Bereznicki L.R. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. Drug Saf. 2016;39(9):847-57. doi: 10.1007/s40264-016-0444-7.
  34. Lea M., Mowe M., Mathiesen L., et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. PLoS ONE. 2019;14(7):e0220071. Doi: https://doi.org/10.1371/journal.pone.0220071.
  35. Tandon V.R., Khajuria V., Mahajan V., et al. Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India. Indian J. Med. Res. 2015;142(1):33-9. doi: 10.4103/0971-5916.162093.
  36. Oscanoa T.J., Lizaraso F., Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759-70. doi: 10.1007/s00228-017-2225-3.
  37. Leendertse A.J., Van Den Bemt P.M., Poolman J.B., et al. Preventable hospital admissions related to medication (HARM): Cost analysis of the HARM study. Value in Heaith. 2011;14(1):34-40. doi: 10.1016/j.jval.2010.10.024.
  38. Manasse H.R. Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989; 46(5):929-44.
  39. Juntti-Patinen L., Neuvonen P.J. Drug-related deaths in a university central hospital. Eur J Clin Pharmacol. 2002;58(7):479-82. doi: 10.1007/s00228-002-0501-2.
  40. WHO 2013. European Hospital Morbidity Database. Availableat: http://data.euro.who.int/hmdb/index.php. Accessed 3 Sept 2014.
  41. European Commission. Proposal for a regulation amending, as regards pharmacovigilance of medicinal products for human use. Regulation (EC) No 726/2004. Impact assessment. 2008. Available at: http://ec.europa.eu/health/files/pharmacos/ pharmpack_12_2008/pharmacovigilance-iavol1_en.pdf. Accessed 3 Apr 2020.
  42. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-205.
  43. Meier F., Maas R., Sonst A., et al. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol. Drug Saf. 2015;24(2):176-86. doi: 10.1002/pds.3663.
  44. Johnson J.A., Bootman J.L. Drug-related morbidity and mortality. Arch Intern Med. 1995;155(18):1945-56.
  45. Ernst F.R., Grizzle A.J. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41(2):192-99. doi: 10.1016/s1086-5802(16)31229-3.
  46. Writing Group Members, Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the Am. Heart Associat. Circulat. 2016;133(4):e38-360. doi: 10.1161/CIR.0000000000000350.
  47. Samp J.C. Touchette D.R., Marinac J.S., Kuo G.M; American College of Clinical Pharmacy Practice-Based Research Network Collaborative. Economic evaluation of the impact of medication errors reported by U.S. clinical pharmacists. Pharmacother. 2014;34(4):350-57. doi: 10.1002/phar.1370.
  48. Encinosa W.E., Bae J. Will meaningful use electronic medical records reduce hospital costs? Am J Manag Care. 2913;19(10 Spec. No):eSP19-25.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2020

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>